Glucagon Blood Test Explained: What It Measures and Why It's Ordered

This page is for educational purposes only and is not medical advice; consult a licensed physician about any laboratory result, symptom or treatment decision. Nothing here interprets an individual test result, and no reference ranges are offered as guidance — reference intervals are assay-specific and belong to the reporting laboratory and the ordering clinician.

What Glucagon Is and Where It Comes From

Glucagon is a 29-amino-acid peptide hormone released by the alpha cells of the pancreatic islets. A 2024 review of clinical glucagon research described glucagon as a counter-regulatory hormone that acts primarily on the liver to increase glucose output, and summarised renewed interest in its wider metabolic roles (PMID 39101175). Glucagon is cut from a larger precursor, proglucagon; a 2022 review explained that the same precursor is processed differently in intestinal L cells to yield GLP-1, GLP-2, oxyntomodulin and glicentin, which is why several circulating peptides share sequence with glucagon (PMID 35990325).

Whether glucagon is produced outside the pancreas has been a long-running question. A 2019 review of extrapancreatic glucagon examined reports of glucagon-like immunoreactivity persisting in people and animals after pancreatectomy and discussed the gut as a candidate source, while noting that assay specificity complicates the interpretation of those observations (PMID 29944966).

Beyond glucose, researchers have described glucagon as a regulator of amino acid metabolism. A 2019 commentary used the term "glutaminostatin" to frame glucagon as a hormone that lowers plasma amino acid concentrations by driving hepatic amino acid turnover, within a feedback loop between the liver and the alpha cell (PMID 31254453).

What a Glucagon Blood Test Actually Measures

A glucagon test quantifies immunoreactive glucagon in a blood sample — most commonly plasma rather than serum. A 2019 methods paper setting out guidelines for measuring glucagon in plasma reported that pre-analytical conditions, including tube type, sample handling and the use of enzyme inhibitors, materially affect measured concentrations, and that these conditions must be standardised before results from different laboratories can be compared (PMID 31671667).

The assays themselves have changed over time. A 2024 review of clinical glucagon measurement traced the move from early radioimmunoassays, which recognised a single epitope, to sandwich ELISAs that require two antibodies binding both ends of the intact 29-amino-acid molecule, and to mass-spectrometry-based approaches (PMID 39101188). A 2017 dissertation-based review on the measurement of gastrointestinal hormones reported that many commercial kits for gut and islet peptides had not been adequately validated for specificity and sensitivity, and argued that assay validation should precede physiological conclusions (PMID 29115211).

Why Clinicians Order Glucagon Measurements

In the published literature, glucagon measurement appears in several distinct contexts.

Evaluating unexplained hypoglycaemia

Glucagon is one of the hormones whose behaviour is examined when low blood glucose has no obvious cause. A 2004 review of hyperinsulinaemic hypoglycaemia in adults described the diagnostic work-up of endogenous hyperinsulinism, in which insulin, C-peptide and counter-regulatory responses are assessed together to separate insulinoma and related conditions from other causes of low glucose (PMID 15122101).

Diabetes and the alpha cell

A 2023 review of newly discovered knowledge on glucagon reported that inappropriate glucagon secretion contributes to hyperglycaemia in diabetes and that improved assays had allowed researchers to re-examine alpha-cell behaviour that older methods could not resolve (PMID 37052948). An earlier 2006 review on glucagon excess and deficiency discussed how both states alter insulin action and hepatic glucose handling (PMID 16530126).

Obesity and proglucagon biology

A 2022 review of glucagon and other proglucagon-derived peptides in obesity reported that glucagon influences energy expenditure, hepatic lipid handling and satiety signalling alongside its glucose effects, and that these overlapping peptides are a reason assay specificity matters in metabolic studies (PMID 35990325).

States that complicate interpretation

The 2019 extrapancreatic glucagon review reported that measurable glucagon-like immunoreactivity has been described in individuals without a functioning pancreas, which the authors discussed as a challenge both for physiology and for interpreting elevated values (PMID 29944966).

Glucagon as a Stimulus Rather Than the Analyte

Confusingly, the phrase "glucagon test" is used in two different ways. In some protocols glucagon is the hormone being measured; in others it is the agent given to provoke the release of a different hormone, which is then measured.

A 2010 review of testing for growth hormone deficiency in adults described the glucagon stimulation test among the provocative tests used when the insulin tolerance test is unsuitable, and discussed the comparative performance and practical limitations of the available options (PMID 20616504). In paediatrics, a 2024 review of the diagnosis of polyuria–polydipsia syndrome discussed glucagon-stimulated copeptin measurement among newer approaches intended to separate central diabetes insipidus (arginine vasopressin deficiency) from primary polydipsia in children (PMID 38164825). In both settings the result of interest is growth hormone or copeptin, not glucagon itself.

What Published Studies Associate With High Glucagon Values

Reviews have linked higher circulating glucagon to several metabolic states, although they also caution that some historical associations rested on assays that measured more than intact glucagon.

• Type 2 diabetes. A 2023 review reported that relative hyperglucagonaemia — glucagon that fails to fall appropriately after a meal — contributes to excessive hepatic glucose production in diabetes (PMID 37052948).
• Obesity and fatty liver. The 2022 proglucagon review discussed hepatic glucagon resistance and elevated glucagon in obesity-associated liver disease as an area of active investigation (PMID 35990325).
• Disrupted amino acid handling. The 2019 glutaminostatin commentary reported that impaired glucagon signalling at the liver raises plasma amino acids, which in turn drive alpha-cell activity and higher glucagon (PMID 31254453).
• Measurement artefact. A 2024 review of glucagon measurement reported that non-specific assays can over-read glucagon by detecting proglucagon fragments, particularly in renal impairment and after pancreatic surgery (PMID 39101188).

None of these associations is a diagnosis. A single elevated number, read outside the clinical picture and without knowing the assay used, does not establish a cause; reviews of clinical glucagon research have repeatedly framed glucagon values as one input among many (PMID 39101175).

What Published Studies Associate With Low or Blunted Values

A 2006 review of glucagon excess and deficiency described glucagon deficiency states and their consequences for insulin action and glucose counter-regulation (PMID 16530126). In the setting of low blood glucose, the 2004 review of adult hyperinsulinaemic hypoglycaemia reported that suppressed counter-regulation alongside inappropriately preserved insulin secretion is the pattern that points toward endogenous hyperinsulinism (PMID 15122101). The 2024 clinical glucagon review also noted that alpha-cell responses can be blunted in long-standing diabetes, which is one reason glucagon is studied dynamically rather than at a single time point (PMID 39101175).

Assay and Interpretation Caveats: What Studies Report

The literature on glucagon measurement is unusually blunt about its own limitations.

1. Antibody specificity. The 2017 review of gastrointestinal hormone measurement reported that several commercially available kits lacked documented specificity, so published "glucagon" values are not always comparable between studies (PMID 29115211).
2. Pre-analytical handling. The 2019 methods and guidelines paper reported that collection and processing conditions influence measured plasma glucagon and recommended standardisation for research and clinical use (PMID 31671667).
3. Assay generation. The 2024 measurement review reported that sandwich ELISA and mass-spectrometry methods improved discrimination of intact glucagon from related peptides compared with older single-epitope assays (PMID 39101188).
4. Physiological context. Because glucagon moves with fasting, feeding and glucose concentration, the 2023 review emphasised interpreting glucagon alongside simultaneous glucose and insulin rather than alone (PMID 37052948).
5. Unexpected sources. The 2019 extrapancreatic glucagon review reported that glucagon-like immunoreactivity detected in unusual clinical situations may not reflect pancreatic secretion (PMID 29944966).

Stimulation Protocols and Practical Limits: What Studies Report

Where glucagon is given as a provocative agent, reviews have discussed trade-offs rather than presenting it as uniformly preferable. The 2010 review of adult growth hormone deficiency testing reported that each provocative test carries its own limitations in reproducibility, duration and tolerability, and described the glucagon stimulation test as an alternative used when insulin-induced hypoglycaemia is contraindicated or impractical (PMID 20616504). The 2024 paediatric review of polyuria–polydipsia diagnosis similarly discussed the comparative practicality of stimulation approaches in children, where prolonged water deprivation is burdensome (PMID 38164825). This page does not describe how such protocols are performed; that is the domain of the supervising clinical team.

Who Interprets the Result

Glucagon results are interpreted by the ordering clinician in the context of the clinical question, the simultaneous glucose and insulin values, kidney and liver function, medications and the specific assay used by the laboratory. The reviews above consistently reported that assay generation and sampling conditions change what the number means (PMID 31671667, PMID 39101188). Readers with a result in hand should bring it to the clinician who ordered it; this page describes what the literature says about the test, not about any individual.

References

• Advances in clinical research on glucagon (Diabetology International, 2024)
• Advances in the clinical measurement of glucagon: from diagnosis to therapy (Diabetology International, 2024)
• Newly discovered knowledge pertaining to glucagon and its clinical applications (Journal of Diabetes Investigation, 2023)
• Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity (Frontiers in Nutrition, 2022)
• Methods and Guidelines for Measurement of Glucagon in Plasma (International Journal of Molecular Sciences, 2019)
• Glutaminostatin: Another facet of glucagon as a regulator of plasma amino acid concentrations (Journal of Diabetes Investigation, 2019)
• Extrapancreatic glucagon: Present status (Diabetes Research and Clinical Practice, 2019)
• Measurement of Gastrointestinal Hormones (Danish Medical Journal, 2017)
• Glucagon: the effects of its excess and deficiency on insulin action (Nutrition, Metabolism and Cardiovascular Diseases, 2006)
• Hyperinsulinemic hypoglycemia in adults (Annales d'Endocrinologie, 2004)
• Testing growth hormone deficiency in adults (Frontiers of Hormone Research, 2010)
• Paediatric perspectives in the diagnosis of polyuria-polydipsia syndrome (Clinical Endocrinology, 2024)